Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PBYI – Puma Biotechnology, Inc.

Float Short %

7.38

Margin Of Safety %

4

Put/Call OI Ratio

0.13

EPS Next Q Diff

0.24

EPS Last/This Y

-0.08

EPS This/Next Y

-0.05

Price

5.24

Target Price

3

Analyst Recom

4

Performance Q

61.54

Relative Volume

1.29

Beta

1.3

Ticker: PBYI




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25PBYI3.280.070.002191
2025-07-28PBYI3.350.070.002197
2025-07-29PBYI3.180.070.002197
2025-07-30PBYI3.160.070.002203
2025-07-31PBYI3.110.071.002209
2025-08-01PBYI3.060.070.002213
2025-08-04PBYI3.180.070.002216
2025-08-05PBYI3.210.070.002229
2025-08-06PBYI3.260.071.672229
2025-08-07PBYI3.30.070.002245
2025-08-08PBYI3.690.070.032302
2025-08-11PBYI4.850.070.042518
2025-08-12PBYI4.860.050.015265
2025-08-13PBYI5.30.050.015069
2025-08-14PBYI5.320.050.004777
2025-08-15PBYI5.720.050.054913
2025-08-18PBYI4.990.020.024543
2025-08-19PBYI5.090.021.804716
2025-08-20PBYI5.10.120.005199
2025-08-21PBYI5.220.125.905193
2025-08-22PBYI5.240.130.005269
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25PBYI3.28320.0- 0.69
2025-07-28PBYI3.34320.0- 0.69
2025-07-29PBYI3.18240.0- 0.69
2025-07-30PBYI3.16240.0- 0.69
2025-07-31PBYI3.11240.0- 0.69
2025-08-01PBYI3.07240.0- 0.69
2025-08-04PBYI3.18240.0- 0.69
2025-08-05PBYI3.22240.0- 0.69
2025-08-06PBYI3.26240.0- 0.69
2025-08-07PBYI3.29240.0- 0.69
2025-08-08PBYI3.69240.0- 0.69
2025-08-11PBYI4.84240.0- 0.69
2025-08-12PBYI4.86-80.0- 0.69
2025-08-13PBYI5.30-80.0- 0.69
2025-08-14PBYI5.32-80.0- 0.69
2025-08-15PBYI5.72-80.0- 0.70
2025-08-18PBYI5.01-80.0- 0.70
2025-08-19PBYI5.09-80.0- 0.70
2025-08-20PBYI5.10-80.0- 0.70
2025-08-21PBYI5.21-80.0- 0.70
2025-08-22PBYI5.24-80.0- 0.70
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25PBYI-1.474.416.97
2025-07-28PBYI-1.474.026.97
2025-07-29PBYI-1.474.026.97
2025-07-30PBYI-1.474.026.97
2025-07-31PBYI-1.474.026.97
2025-08-01PBYI-1.474.026.97
2025-08-04PBYI-1.475.096.97
2025-08-05PBYI-1.475.096.97
2025-08-06PBYI-1.475.096.97
2025-08-07PBYI-1.475.096.97
2025-08-08PBYI-1.475.096.97
2025-08-11PBYI-1.455.076.87
2025-08-12PBYI-1.455.077.34
2025-08-13PBYI-1.455.077.34
2025-08-14PBYI-1.455.077.34
2025-08-15PBYI-1.455.077.34
2025-08-18PBYI-1.456.227.34
2025-08-19PBYI-1.456.227.38
2025-08-20PBYI-1.436.227.38
2025-08-21PBYI-1.436.227.38
2025-08-22PBYI-1.436.227.38
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.12

Avg. EPS Est. Current Quarter

0.09

Avg. EPS Est. Next Quarter

0.36

Insider Transactions

-1.43

Institutional Transactions

6.22

Beta

1.3

Average Sales Estimate Current Quarter

51

Average Sales Estimate Next Quarter

66

Fair Value

5.47

Quality Score

97

Growth Score

47

Sentiment Score

79

Actual DrawDown %

62.9

Max Drawdown 5-Year %

-88

Target Price

3

P/E

5.36

Forward P/E

16.25

PEG

P/S

1.11

P/B

2.5

P/Free Cash Flow

5.98

EPS

0.98

Average EPS Est. Cur. Y​

0.7

EPS Next Y. (Est.)

0.65

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

20.35

Relative Volume

1.29

Return on Equity vs Sector %

21.6

Return on Equity vs Industry %

34.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

Puma Biotechnology Inc
Sector: Healthcare
Industry: Biotechnology
Employees: 172
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
stock quote shares PBYI – Puma Biotechnology, Inc. Stock Price stock today
news today PBYI – Puma Biotechnology, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PBYI – Puma Biotechnology, Inc. yahoo finance google finance
stock history PBYI – Puma Biotechnology, Inc. invest stock market
stock prices PBYI premarket after hours
ticker PBYI fair value insiders trading